AbbVie June 15th Short Interest Update

AbbVie (NYSE:ABBV) has witnessed a rise of 194.8% or 51,685,717 shares in its short figure. The short interest augmentation took it from 26,528,384 on May 31,2016 to 78,214,101 on June 15,2016. In terms of floated shares, the short interest was calculated to be 4.8%. The days to cover are 7 given that the daily volume averaged 11,056,328 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.

AbbVie (NYSE:ABBV): The stock opened at $59.26 on Friday but the bulls could not build on the opening and the stock topped out at $60.60 for the day. The stock traded down to $59.18 during the day, due to lack of any buying support eventually closed down at $59.86 with a loss of -2.37% for the day. The stock had closed at $61.31 on the previous day. The total traded volume was 9,878,541 shares.

The company shares have dropped -10.90% from its 1 Year high price. On Jul 21, 2015, the shares registered one year high at $71.60 and the one year low was seen on Oct 22, 2015. The 50-Day Moving Average price is $61.52 and the 200 Day Moving Average price is recorded at $58.18.

AbbVie (NYSE:ABBV) has tumbled 0.25% during the past week and has dropped 4.54% in the last 4 week period. The company has outperformed the S&P 500 by 1.41% in the past week but underperformed the index by 1.66% in the last 4 weeks.

AbbVie Inc. (AbbVie) is a global, research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Companys products are focused on treating conditions, such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis and Crohns disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinsons disease; complications associated with chronic kidney disease and cystic fibrosis, and other health conditions, such as low testosterone. AbbVie also has a pipeline of new medicines, including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties, such as immunology, virology/liver disease, oncology, renal disease, neurological diseases and womens health. The Companys product portfolio includes HUMIRA, HCV products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *